Importance of measuring non-HDL cholesterol in type 2 diabetes patients. by Ram, Nanik et al.
eCommons@AKU
Department of Medicine Department of Medicine
February 2014
Importance of measuring non-HDL cholesterol in
type 2 diabetes patients.
Nanik Ram
Aga Khan University
Bilal Ahmed
Aga Khan University, bilal.ahmed@aku.edu
Fauzan Hashmi,
Aga Khan University
ABDUL Jabbar
Aga Khan University
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Endocrinology, Diabetes, and Metabolism Commons
Recommended Citation
Ram, N., Ahmed, B., Hashmi,, F., Jabbar, A. (2014). Importance of measuring non-HDL cholesterol in type 2 diabetes patients..
JPMA. The Journal of the Pakistan Medical Association, 64(2), 124-128.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med/499
Introduction
Non-high-density lipoprotein (Non-HDL) cholesterol has
been shown to be superior predictor of cardiovascular
risk,1 because it contains cholesterol of all atherogenic
particles, including low density lipoprotein (LDL),
Lipoprotein A, very-low-density lipoprotein (VLDL),VLDL
remnant and intermediate-density lipoprotein.2,3
Currently LDL cholesterol is the primary treatment target of
lipid-lowering therapy in primary and secondary
prevention of cardiovascular diseases.4,5 However, despite
achieving the LDL goal, patients still develop recurrent
coronary artery disease (CAD).6 One possible explanation of
this residual risk could be a still high Non-HDL cholesterol in
these patients despite achieving the LDL target. Adult
Treatment Panel-III (ATP-III) guidelines recommend a Non-
HDL cholesterol as a secondary treatment target among
those with triglycerides level above 200md/dl.7 However,
no triglyceride cut-off level was defined by the American
College of Cardiology Foundation and the American
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Abstract
Objective: To study the correlation between Non-high-density lipoprotein and low-density lipoprotein cholesterol
in patients with Type 2 diabetes mellitus and the proportion of patients achieving Adult Treatment Panel III
recommended goals.
Methods: The cross sectional study was conducted at the Diabetic Clinic, Aga Khan University Hospital, Karachi. Data
of Type 2 diabetes mellitus patients who attended the clinic bewteen 2007 and 2011 was reviewed. All Type 2 diabetic
patients of either gender with fasting lipid profile irrespective of taking lipid lowering therapy were included. Type-1
DM, gestational diabetes, type 2 diabetes patients with pregnancy and those with incomplete data were excluded.
Correlation between the low-density lipoprotein and Non- high-density lipoprotein was assessed by applying Cramer
V and phi. Proportion of patients achieving Adult Treatment Panel III recommended goals was checked. Multivariable
regression was done to identify common factors associated with elevated Non- high-density lipoprotein cholesterol.
Results: A total of 1352 patients fulfilling the eligibility criteria were included in the study. Mean age of the patients
was 54.5±11.3 years; 797 (59%) were males; 1122 (83%) had Body Mass Index above 25; and 1016 (75%) had HbA1c
>7%. Mean Non-high-density lipoprotein cholesterol was 129±42mg/dl. Mean low-density lipoprotein cholesterol
was 100±37mg/dl. Both low-density lipoprotein <100 and Non-HDL <130 mg/dl was achieved in 645 (48%) patients.
It is important to note that although 728 (53.8%) patients achieved target LDL cholesterol of <100mg/dl, among
them 83 (11.4%) had Non-high-density lipoprotein cholesterol still above the target >130mg/dl (p<0.05). Out of 752
patients with Non-high-density lipoprotein cholesterol <130mg/dl, 645(86%) had low-density lipoprotein
cholesterol below 100mg/dl. Cramer V and Phi showed that correlation between Non-high-density lipoprotein and
low-density lipoprotein cholesterol was 0.71 (pvalue<0.01). After adjusting for other covariates, low-density
lipoprotein cholesterol >100mg/dl was independently associated with having Non-high-density lipoprotein
cholesterol >130mg/dl (Adjusted Odds Ratio 38.6; 95% Confidance Interval = 28.1-53.1). Similarly, age <60 years was
60% more likely to have Non-high-density lipoprotein cholesterol> 130 mg/dl (Adjusted Odds Ratio 1.6; 95%
Confidance Interval = 1.01 - 2.3). Whereas having obesity Body Mass Index >25 was 3.6 times more associated to
have Non-high-density lipoprotein >130mg/dl (Adjusted Odds Ratio 3.6; 95% Confidance Interval = 1.6-7.7). In
patients with coronary artery disease, combined goal achievement of low-density lipoprotein <70mg/dl and Non-
high-density lipoprotein cholesterol <100mg/dl was seen in 59(35%). Among patients with high-density lipoprotein
<70mg/dl, 8(10%) had Non-high-density lipoprotein >100mg/dl (p <0.05). 
Conclusion: The study showed a correlation between Non-high-density lipoprotein and low-density lipoprotein
cholesterol. As measuring Non-high-density lipoprotein cholesterol in Type 2 DM patients is simple, cost-effective
and convenient because it does not require 12-hour fasting which may be a risk for hypoglycaemia in these patients,
clinicians may choose Non-high-density lipoprotein as a routine measure in everyday practice.
Keywords: Type 2 diabetes mellitus, Non-high-density lipoprotein (Non-HDL) cholesterol, Low-density lipoprotein
(LDL) cholesterol, Coronary artery disease. (JPMA 64: 124; 2014)
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Diabetes Association (ADA).8
Apolipoprotein B100 (Apo B) molecule is present in all
major atherogenic particles (VLDL, IDL, LDL). Therefore,
estimating Apo B has been shown as a superior indicator
of cardiovascular risk than total or LDL cholesterol.9 Apo B
measurement is not readily available of cost-effective,10
but the correlation co-efficient for Non-HDL and Apo B is
significantly better than that of LDL and Apo B.11 Now it is
well recognised that non-HDL and Apo B are closely
related metabolically and they can substitute each other.9
Non-HDL cholesterol (NHDL-C) is calculated from lipid
profile by subtracting HDL-C from total cholesterol. It is
simple, inexpensive and, most important, does not
require a 12-hour fast because it can be calculated on
random serum sample. Therefore, the current study was
planned to determine the correlation between Non-HDL
and LDL cholesterol. If correlated, physicians can use Non-
HDL cholesterol as a close marker of Apo B. 
Treatment goal for Non-HDL is 30mg/dl above the LDL
target. For diabetic patients without CAD, treatment
target for LDL and Non-HDL is <100mg/dl and <130mg/dl
respectively. For diabetic patients with CAD, treatment
target for LDL is <70 and Non-HDL cholesterol is
<100mg/dl.7
Targeting Non-HDL cholesterol in diabetic patients is even
more important because these patients often have
atherogenic dyslipidaemia characterised by low HDL
cholesterol and high triglycerides with resultant increase
in Non-HDL cholesterol than elevated LDL alone.12 Many
diabetic patients are not at recommended levels for Non-
HDL and LDL cholesterol. 
The primary objective of the present study was to
determine the correlation between Non-HDL and LDL
cholesterol in type 2 diabetes mellitus (T2DM) patients.
Secondary objectives were to identify proportion of T2DM
patients achieving ATP III-guideline recommended goals
and factors associated with elevated Non-HDL
cholesterol.
Patients and Methods
The cross-sectional study was conducted at the Diabetic
Clinic of Aga Khan University Hospita, Karachi, and
comprised data of patients having visited the clincs
between 2007 and 2011. Patients >18 years of age,
already diagnosed to have known diabetes visiting
endocrine/diabetes clinic were identified from hospital
medical records. AKUH is a largest tertiary care hospital in
the metropolitan city of Karachi with a population of 18
million. Information about demographic characteristics,
clinical presentations and laboratory biochemical
parameters were collected. The study was approved by
the hospital ethical review committee.
All T2DM patients of either gender with fasting lipid
profile irrespective of receiving lipid-lowering therapy
were included. Exclusion criteria were type 1 diabetes,
gestational diabetes, and T2DM patients with pregnancy.
A structured questionnaire was used for data collection.
Complete demographic and clinical history, including,
hypertension, CAD, body mass index (BMI), HbA1C, Non-
HDL and LDL cholesterol were identified. BMI 18-22.9
Kg/m2 was defined as normal; 23-24.9 Kg/m2 as
overweight; and >25 Kg/m2 as obese, according to an
Asian cutoffs; HbA1c >7 as uncontrolled T2DM; and <7 as
controlled T2DM according to ADA criteria; Non-HDL
cholesterol, according to ATP-III, target was <130mg/dl in
T2DM patients without CAD; with CAD target was
<100mg/dl;13 target for LDL cholesterol in T2DM patients
without CAD was 100mg/dl; and with CAD was 70
mg/dl,13 hypertension was defined as blood pressure
>140/90mmHg or patients maintained on oral anti-
hypertensive medication. 
Data was entered and analyzed in SPSS version 17.0.
Mean±SD, ranges were calculated for continuous
variables and proportions for categorical variables. To see
the difference between two groups independent student
t-test, chi square or Fisher exact was used where
appropriate. Continuous variables were checked for their
linearity by doing quartile and Box Tidwell analysis. The
trends in values of Exp (b) i.e. log of odds of outcome,
either increasing or decreasing and confidence interval
(CI) either overlapping or not were checked. If the CI was
found to be overlapping with increasing or decreasing
Exp (b) trend, then it was taken as continuous variable.
Along with this for every continuous variable higher order
terms were made like log, quadratic, cube and box-Tidwell
transformation. All those variables found to be
insignificant were kept as a continuous one. However, in
our case, the values for BMI, and age came to be
significant, hence, we formed categories. Correlation
between the LDL and NHDL was assessed by applying
Cramer V and phi. Multicolinearity was checked among
independent variables, between nominal variables it was
checked through Cramer's V and phi, between nominal
and continuous through eta, and between continuous
variables it was checked through Pearson correlation. The
cutoff of 0.8 was considered as an Interco relation among
independent variables. A univariate logistic regression
analysis was conducted to assess the (crude) association
of the prognostic factors for Non-HDL. Biological
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significance and a value of p<0.25 were considered
significant at univariate analysis. Biological plausible
interactions among variables and confounding factors
were also checked. Multivariable logistic regression was
done and results were expressed as odds ratios (OR),
along with 95% CI.
Results
A total of 1352 patients fulfilling the eligibility criteria
were included in the study. Mean age of the patients was
54.5±11.3 years; 797 (59%) were males; 1122 (83%) had
BMI above 25; 335 (24.8%) had HbA1c <7%; 630 (46.6%)
had HbA1c 7-9%; while 386 (28.6%) patients had HbA1c
>9%. There was history of hypertension in 540 (40%)
patients (Table-1). Mean Non-HDL cholesterol was
129±42mg/dl. Mean LDL cholesterol was 100±37mg/dl.
Both LDL <100mg/dl and Non-HDL <130mg/dl targets
were achieved in 645 (48%) patients. Although 728
(53.8%) patients achieved the target LDL of <100mg/dl,
83 (11.4%) among them had Non-HDL cholesterol above
target >130mg/dl (p<0.05). Out of 752 patients with Non-
HDL cholesterol <130mg/dl, 645(86%) had LDL
cholesterol below 100 mg/dl. Cramer V and Phi showed
that correlation between Non-HDL and LDL cholesterol
was 0.71 (p<0.01).
Unadjusted odds ratios were worked out (Table-2). Age <60
years (OR 1.8; 95% CI = 1.4-2.4), being female (OR 1.2; 95%
CI = 1.1-1.5), BMI >25 (OR 2.5; 95% CI = 1.4-4.5) and HbA1c
>9% (OR 1.6; 95% CI = 1.2 - 2.2) were associated with having
Non-HDL cholesterol >130mg/dl. After adjusting for other
covariates, LDL cholesterol >100mg/dl was independently
associated with having Non-HDL >130mg/dl (Adjusted OR
38.6; 95% CI= 28.1-53.1). Similarly, age <60 years was 60%
more likely to have Non-HDL >130mg/dl (Adjusted OR 1.6;
95% CI= 1.01-2.3). Having BMI>25 was 3.6 times more
associated to have Non-HDL cholesterol >130mg/dl
(Adjusted OR 3.6; 95% CI= 1.6-7.7).
In patients with CAD, combined goal achievement of LDL
<70 and Non-HDL <100 was seen in 59(35%) patients.
Among these patients with LDL <70mg/dl, 8(10%)
patients had Non-HDL >100mg/dl (p <0.05) (Table-3). 
Discussion
Correlation between Non-HDL and LDL cholesterol at 71%
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Table-1: Prevalence of Non-HDL <130 and Non-HDL > 130 mg/dl according to Age,
Gender, BMI, HBA1C, LDL cholesterol and history of hypertension.
Variable NHDL <130 NHDL >130 P-Value Unadjusted 95% CI
odds ratios
Age
< 60 492 (65.4) 469 (78.2) < 0.001 1.8 1.4-2.4
> 60 260 (34.6) 131 (21.8) Ref 
Gender
Male 463 (61.6) 335 (55.8) 0.03 Ref 
Female 289 (38.4) 265 (44.2) 1.2 1.1-1.5
BMI
18-22.9 51 (6.8) 16 (2.7) 0.001 Ref 
23-24.9 81 (10.8) 80 (13.3) 3.1 1.6-5.9
> 25 620 (82.4) 504 (84) 2.5 1.4-4.5
HbA1c
< 7 203 (27) 132 (22) 0.001 Ref 
7-9 365 (48.5) 266 (44.3) 1.1 0.8-1.4
> 9 184 (24.5) 202 (33.7) 1.6 1.2-2.2
LDL
< 100 645 (85.8) 83 (13.8) 0.000 Ref 
>100 107 (14.2) 517 (86.2) 37.5 27.5-51.1
HTN
No 420 (55.9) 394 (69.7) < 0.001 --
Yes 332 (44.1) 206 (34.3) --
Non-HDL: Non-High Density Lipoprotein. BMI: Body Mass Index. HbA1c: Glycated Haemoglobin.
LDL: Low Density Lipoprotein.
Table-2: Adjusted Odds along with 95% Confidence Interval showing predictors for
Non-HDL cholesterol >130mg mg/dl.
Variable Adjusted ORs 95% CI P-value
LDL
<100 1
>100 38.6 28.1 - 53.1 0.00
Age 
> 60 1
<60 1.6 1.01- 2.3 0.03
BMI
18-22.9 1
23-24.9 2.6 1.1 - 6.2 0.00
>25 3.6 1.6 - 7.7
Non-HDL: Non-High Density Lipoprotein. LDL: Low Density Lipoprotein. BMI: Body Mass Index.
Table-3: Coronary Artery Disease Patients Characteristics (n=169).
Variable NHDL <100 N (%) NHDL > 100 N (%) P-Value
Age
<60 39 ( 43.8) 49 (61.3) 0.02
> 60 50 (56.2) 31 (38.8)
Gender 
Male 67 (75.3) 50 (62.5) 0.07
Female 22 (24.7) 30 (37.5)
BMI
18-22.9 10 (11.2) 3 (3.8) 0.18
23-24.9 8 ( 9 ) 7 (8.8)
>25 71 (79.8) 70 (87.5)
LDL
<70 59 (66.3) 8 (10) 0.00
> 70 30 (33.7) 72 (90)
Non-HDL: Non-High Density Lipoprotein. BMI: Body Mass Index. LDL: Low Density Lipoprotein.
was observed in the current study, which emphasise the
importance of measuring and targeting it in T2DM
patients. Non-HDL and LDL cholesterol combined target
was achieved in 48% of T2DM patients. Despite LDL level
<100mg/dl, 11% of patients had Non-HDL cholesterol
above the target range.
Atherogenic dyslipidaemia is associated with an
increased risk of future cardiovascular complications.14-17
The association between abnormal lipid levels and
cardiovascular risk is much more evident among patients
with diabetes mellitus and hypertension.18 Current
guidelines emphasise the importance of lipid goal
attainment in this high-risk group.7,13 Non-HDL
cholesterol proves a better predictor of vascular events.19
Despite LDL cholesterol being in the target range,
achieving Non-HDL cholesterol goal is still poor.20,21
Patient need 12-14 hour fasting for measuring LDL
cholesterol which may cause risk of hypoglycaemia in a
diabetic patient. Non-HDL cholesterol calculated from
random serum sample, simple, convenient, cost-effective
and, most importantly, it is a valid surrogate marker of
Apo B in diabetic patients.9
A study reported 64.6%, 71.5% patients with diabetes not
achieving LDL <100md/dl and Non-HDL <130mg/dl
respectively.21 Another study examined the LDL and non-
HDL goal in coronary heart disease patients. It found that
74% of the patients attained LDL goal while only 51%
achieved combined non-HDL and LDL cholesterol in
range.22 The current study observed combined
LDL<70mg/dl and Non-HDL<100mg/dl in 35% of patients
with diabetes and CAD, while another study reported 13%
of such goal achievement in very high-risk CAD patients.22
In a study from Saudi Arabia, 77% T2DM patients had
LDL> 100md/dl23 while San Antonio heart study found
50% of patients with T2DM had high-risk LDL cholesterol
level.24
Possible explanations for poor Non-HDL goal
achievement are Non-HDL cholesterol not reported in
routine lipid profile panel, lack of physicians/healthcare
provider awareness regarding its importance, how to
calculate Non-HDL cholesterol, failure to intensify lipid
lowering therapy once LDL cholesterol is in target to
achieve Non-HDL cholesterol level.
It has been suggested that direct reporting of Non-HDL-C
on standard lipid profile result would improve goal
achievement.25
High BMI, high HbA1c and younger age group were
independently associated with high Non-HDL cholesterol
in our study. Similar results have been identified in a high-
risk group of patients.26
There were certain limitations in our study. Due to
observational nature of the study, there was no data on
use of statins, so we were unable to determine the effect
of statin and therapeutic lifestyle changes on Non-HDL
and LDL cholesterol goals. Similarly, cause and effect
relationship could not be ascertained.
Conclusion 
The results showed correlation between Non-HDL and
LDL cholesterol. As measuring Non- HDL cholesterol in
T2DM patients is simple, cost-effective and convenient
because it does not require 12-hour fasting, which may be
a risk for hypoglycaemia in these patients, clinicians may
choose Non-HDL as a routine measure in everyday
practice. It also showed that about 44% of patients did not
achieve Non-HDL cholesterol targets. More aggressive
lipid-lowering therapy, as such, should be implemented.
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